| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439554 | European Journal of Cancer | 2018 | 8 Pages |
Abstract
The SBG 2000-1 study failed to show a statistically significant improvement of escalated and tailored-dosed chemotherapy compared with standard BSA-based chemotherapy in patients with low haematological toxicity, although all efficacy parameters showed a numerical advantage for tailored treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
H. Lindman, M. Andersson, J. Ahlgren, E. Balslev, A. Sverrisdottir, S.B. Holmberg, N.O. Bengtsson, E.H. Jacobsen, A.B. Jensen, J. Hansen, M.K. Tuxen, L. Malmberg, K. Villman, H. Anderson, B. Ejlertsen, J. Bergh, C. Blomqvist,